Production (Stage)
E
Hoth Therapeutics, Inc. HOTH
$1.19 -$0.11-8.46% NASDAQ
Recommendation
Prev Close
$1.30
Volume
1,434,809
Avg Vol (90D)
1,014,081
Market Cap
$17.17M
Dividend & Yield
--
52-Week Range
$0.58 - $3.80
P/E (TTM)
--
EPS (TTM)
-$1.15
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough ...
6/5/2025 - GuruFocus
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough ...
6/5/2025 - GuruFocus
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
6/5/2025 - PR Newswire
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Lowered by Wall Street Zen
5/24/2025 - Ticker Report
/C O R R E C T I O N -- Hoth Therapeutics, Inc./
5/12/2025 - GuruFocus
/C O R R E C T I O N -- Hoth Therapeutics, Inc./ HOTH Stock News
5/12/2025 - GuruFocus
Hoth Therapeutics (HOTH) Reveals Promising Preclinical Results for HT-KIT Treatment HOTH ...
5/12/2025 - GuruFocus
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense ...
5/12/2025 - GuruFocus
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense ...
5/12/2025 - GuruFocus
Hoth Therapeutics reports preclinical data for HT-KIT
5/12/2025 - The Fly
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers
5/12/2025 - PR Newswire
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy ...
4/17/2025 - GuruFocus
Hoth Therapeutics (HOTH) Secures Key Patent in Japan for RNA-Based Cancer Treatment HOTH ...
4/17/2025 - GuruFocus
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy ...
4/17/2025 - GuruFocus
Hoth Therapeutics granted Japanese patent for novel RNA-based cancer therapy
4/17/2025 - The Fly
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
4/17/2025 - PR Newswire
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial HOTH Stock News
4/15/2025 - GuruFocus
Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment HOTH Stock News
4/15/2025 - GuruFocus
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
4/15/2025 - GuruFocus
Hoth Therapeutics' HT-001 shows efficacy in Phase 2a pruritus trial
4/15/2025 - The Fly
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
4/15/2025 - PR Newswire
Hoth Therapeutics (HOTH) Advances Alzheimer's Research with Washington University Collaboration
4/2/2025 - GuruFocus
Hoth Therapeutics (HOTH) Reports Promising Data for Alzheimer's Candidate HT-ALZ
4/2/2025 - GuruFocus
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing ...
4/2/2025 - GuruFocus
Hoth Therapeutics announces collaboration with Washington University
4/2/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$9.64M
Net Income (TTM)
-$9.62M
Balance Sheet
Total Assets (Q)
$12.36M
Total Debt (Q)
$28.90K
Total Liabilities (Q)
$815.30K
Book Value Per Share (Q)
$0.8762
Cash Flow
Cash from Operations (TTM)
-$8.04M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$11.81M
Net Change in Cash (TTM)
$3.75M
Filings
Filing Date
Monday, May 12, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
0.64
7-Day Total Return
37.21%
30-Day Total Return
39.08%
60-Day Total Return
9.17%
90-Day Total Return
-4.03%
Year to Date Total Return
54.53%
1-Year Total Return
9.17%
2-Year Total Return
-63.04%
3-Year Total Return
-88.64%
5-Year Total Return
-98.36%
52-week Low
Aug 08, 2024 - $0.58
52-week High
Jan 07, 2025 - $3.80
Valuation
Market Cap
$17.17M - Nano Cap
Enterprise Value
$5.88M
Price/Sales (TTM)
--
Price/Book (Q)
1.48
Dividends and Shares
Shares Outstanding
12.73M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
hoththerapeutics.com
Phone Number
(646) 756-2997
Address
1177 Avenue of the Americas
Suite 5066 - 5th Floor
New York, NY 10036
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial... more
NASDAQ 06/09/2025 4:00PM Eastern Quotes delayed